Incidence and course of depression in multiple sclerosis in the multinational BEYOND trial

Schippling, S; O'Connor, P; Knappertz, V; Pohl, C; Bogumil, T; Suarez, G; Cook, S; Filippi, M; Hartung, H P; Comi, G; Jeffery, D R; Kappos, L; Goodin, D S; Arnason, B

Abstract: Early experience in MS generated concerns that interferon beta treatment might provoke onset or worsening of depression. The objective of the study was to compare depression incidence in relapsing-remitting MS patients receiving interferon beta-1b (IFNB-1b) or glatiramer acetate (GA) in the BEYOND trial. 891/897 (99 %) of English, French, Spanish and Italian speakers among 2244 patients randomized (2:2:1) to receive either IFNB-1b 500 µg, 250 µg, or GA 20 mg QD for 2-3.5 years submitted Beck Depression Inventory Second Edition (BDI-II) scores at screening and serially thereafter, in which scores ≥14 indicated depression. Baseline BDI-II scores ≥14 were reported in 232/891 patients (26.3 %), with no meaningful difference among the three treatment arms noted at this or at any other time during the study including trial end. Percentages of patients depressed by BDI-II scores deviated little in any arm at any time (IFNB-1b 500 µg: 24.7 %, IFNB-1b 250 µg: 24.4 %, GA: 32.4 %). Antidepressant usage was likewise similar among the three treatment arms (IFNB-1b 500 µg: 33.7 %, IFNB-1b 250 µg: 31.8 %, GA: 28.8 %) as was depression severity and the frequency with which non-blinded treating physicians recorded depression as an adverse event (IFNB-1b 500 µg: 17.2 %, IFNB-1b 250 µg: 17.0 %, GA: 14.4 %). Treating physicians attributed depression to IFNB-1b 250 µg therapy in 53.6 % and to GA in 21.9 % of instances. This large, prospective, randomized-controlled MS dataset showed no increased risk of depression above baseline values with standard or double-dose IFNB-1b or GA QD treatment.

DOI: https://doi.org/10.1007/s00415-016-8146-8

Published Version

The following work is licensed under a Creative Commons: Attribution 4.0 International (CC BY 4.0) License.

Originally published at:
Schippling, S; O’Connor, P; Knappertz, V; Pohl, C; Bogumil, T; Suarez, G; Cook, S; Filippi, M; Hartung, H P; Comi, G; Jeffery, D R; Kappos, L; Goodin, D S; Arnason, B (2016). Incidence and course of depression in multiple sclerosis in the multinational BEYOND trial. Journal of Neurology, 263(7):1418-1426.
DOI: https://doi.org/10.1007/s00415-016-8146-8
Incidence and course of depression in multiple sclerosis in the multinational BEYOND trial

Sven Schippling\textsuperscript{1} · Paul O’Connor\textsuperscript{2} · Volker Knappertz\textsuperscript{3,4} · Christoph Pohl\textsuperscript{5,6} · Timon Bogumil\textsuperscript{5} · Gustavo Suarez\textsuperscript{7} · Stuart Cook\textsuperscript{8} · Massimo Filippi\textsuperscript{9} · Hans-Peter Hartung\textsuperscript{4} · Giancarlo Comi\textsuperscript{10} · Douglas R. Jeffery\textsuperscript{11} · Ludwig Kappos\textsuperscript{12} · Douglas S. Goodin\textsuperscript{13} · Barry Arnason\textsuperscript{14}

Received: 16 December 2015 / Revised: 25 April 2016 / Accepted: 26 April 2016 / Published online: 13 May 2016
© The Author(s) 2016. This article is published with open access at Springerlink.com

Abstract Early experience in MS generated concerns that interferon beta treatment might provoke onset or worsening of depression. The objective of the study was to compare depression incidence in relapsing–remitting MS patients receiving interferon beta-1b (IFNB-1b) or glatiramer acetate (GA) in the BEYOND trial. 891/897 (99\%) of English, French, Spanish and Italian speakers among 2244 patients randomized (2:2:1) to receive either IFNB-1b 500 µg, 250 µg, or GA 20 mg QD for 2–3.5 years submitted Beck Depression Inventory Second Edition (BDI-II) scores at screening and serially thereafter, in which scores ≥14 indicated depression. Baseline BDI-II scores ≥14 were reported in 232/891 patients (26.3\%), with no meaningful difference among the three treatment arms noted at this or at any other time during the study including trial end. Percentages of patients depressed by BDI-II scores deviated little in any arm at any time (IFNB-1b 500 µg: 24.7\%, IFNB-1b 250 µg: 24.4\%, GA: 32.4\%). Antidepressant usage was likewise similar among the three treatment arms (IFNB-1b 500 µg: 33.7\%, IFNB-1b 250 µg: 31.8\%, GA: 28.8\%) as was depression severity and the frequency with which non-blinded treating physicians recorded depression as an adverse event (IFNB-1b 500 µg: 17.2\%, IFNB-1b 250 µg: 17.0\%, GA: 14.4\%). Treating physicians attributed depression to IFNB-1b 250 µg therapy in 53.6\% and to GA in 21.9\% of instances. This large, prospective, randomized-controlled MS dataset showed no increased risk of depression above baseline values with standard or double-dose IFNB-1b or GA QD treatment.

On behalf of the BEYOND Study Group.

P. O’Connor is now retired.

At the time of the initial manuscript preparation, V. Knappertz was a salaried employee of Bayer HealthCare Pharmaceuticals, Montville, New Jersey, USA.

Christoph Pohl: deceased.

Electronic supplementary material The online version of this article (doi:10.1007/s00415-016-8146-8) contains supplementary material, which is available to authorized users.

Sven Schippling
svenschippling@usz.ch

1 Department of Neuroimmunology and Multiple Sclerosis Research, Department of Neurology, University Medical Center Zurich, Frauenklinikstrasse 26, 8091 Zurich, Switzerland
2 St. Michael’s Hospital, Toronto, Canada
3 Teva Pharmaceuticals, Frazer, PA, USA
4 Department of Neurology, Medical Faculty, Heinrich-Heine-Universität, Düsseldorf, Germany
5 Bayer HealthCare AG/Bayer Pharma AG, Berlin, Germany
6 University Hospital Bonn, Bonn, Germany
7 Bayer HealthCare Pharmaceuticals, Whippany, NJ, USA
8 Rutgers-New Jersey Medical School, Newark, NJ, USA
9 Ospedale San Raffaele, Milan, Italy
10 Vita-Salute University, Milan, Italy
11 Piedmont Health Care, Mooresville, NC, USA
12 Neurology, Departments of Medicine, Clinical Research, Biomedicine and Biomedical Engineering, University Hospital Basel, Petersgraben 4, 4031 Basel, Switzerland
13 University of California at San Francisco, San Francisco, CA, USA
14 Department of Neurology, University of Chicago, Chicago, IL, USA
Keywords Multiple sclerosis · Depression · Clinical trial · Interferon beta · Glatiramer acetate · BEYOND study

Introduction

Multiple sclerosis is an inflammatory, demyelinating disease of the central nervous system that follows an unpredictable course [1]. Multifocal involvement of CNS white and gray matter can produce a multitude of clinical signs and symptoms that can cause accumulating physical impairment and disability. MS is frequently accompanied by cognitive and psychological changes that often lessen patient quality of life, occupational competence, and social interactions [2, 3]. Notably, depression is present at any given point in time in approximately one-quarter of MS patients versus 5% of the population at large. Furthermore, the lifetime incidence of significant depressive symptomatology in MS patients can exceed 50%, considerably higher than the 16% estimated lifetime incidence of major depressive disorder in the US population at large [3–13]. Overall, it is now widely accepted that the rate of suicide in MS is significantly increased as compared to the underlying population [14].

Several interferon beta (IFNB) formulations are used to treat relapsing–remitting MS (RRMS) [6, 15]. Early experience with IFNB was interpreted by regulatory authorities as suggesting agent-related development and worsening of depressive symptoms. When depression develops in IFNB-treated patients, a careful consideration of treatment cessation has been advised [16–19]. In several reports, an association between IFNB therapy and depression has been proposed: included are case studies of individuals suffering from depression after starting IFNB treatment [20], depression recorded as adverse events during clinical trials and depression, accepted as such, based on response to non-validated questionnaires [21]. Yet, depression data collected during clinical trials in MS using validated instruments has consistently failed to document any such association [22].

Perceived links between IFNB and depression may be colored in part by the frequency of underlying depression in the absence of therapy; potential relationships between the distress that often follows a recent diagnosis of MS; dread of injections; the tendency for MS to worsen; and mood alterations triggered by concomitantly administered medications [23]. Depression is a well-established risk factor for suicide by MS patients [2, 24], such that a clear understanding of any association—or its absence—between IFNB therapies and depression is desirable. To this end, we retrospectively compared the incidence and severity of depression in 891 English-, French-, Spanish- and Italian-speaking patients among the 2244 patients enrolled in the Betaseron Efficacy Yielding Outcomes of a New Dose (BEYOND) trial.

Patients and methods

Patients with RRMS were randomized in the BEYOND trial (NCT00099502) to receive either IFNB-1b 250 or 500 μg every other day or glatiramer acetate (GA) 20 mg daily in a 2:2:1 ratio using block randomization with regional stratification [25]. Patients were followed per protocol for 2 years, with patients continuing on randomized therapy until the last entered patient had reached the 2-year study end. Patients randomized early during recruitment were followed for a maximum of up to 3.5 years. Treating physicians and patients were aware of allocation to IFNB or GA, but were blinded to IFNB dose. Evaluating physicians were blinded to all treatment assignments [25]. BEYOND was performed in accordance with Good Clinical Practice and the International Conference on Harmonization (ICH) guidelines. The institutional review boards of all participating centers approved the study protocol. Patients provided written informed consent.

Study population

Treatment-naïve patients with RRMS from 26 countries who met the 2001 McDonald diagnostic criteria for MS [26] were eligible for inclusion in BEYOND if aged between 18 and 55 years, had at least one relapse in the year before study entry, and had a baseline Expanded Disability Status Scale (EDSS) [27] score of ≤ 5. Patients were excluded from the study if they presented with progressive forms of MS, or if they had received either experimental or approved treatment for MS. Importantly, patients with a history of severe depression, a previous suicide attempt, or current suicidal ideation were also excluded.

Assessment of depression

Depression and suicidal ideation were assessed on a quarterly basis (every 12 weeks) using the Beck Depression Inventory Second Edition (BDI-II) [28] in English-, French-, Spanish- and Italian-speaking patients, because validated versions were only available in these languages. The BDI-II is a self-administered rating inventory consisting of 21 items that measures attitudes and symptoms suggestive of depression, including feelings of hopelessness and guilt, irritability and fatigue, as well as sleep patterns and loss of appetite. Each item is rated on an intensity scale of 0–3, with a maximum score of 63. Total scores of ≤13 indicate no or insignificant depression, while scores in the range of 14–19 suggest mild; 20–28, moderate; and ≥ 29, severe depression [28].

Guided by the Goldman Consensus statement recommendations on scoring depression in MS, BDI-II scores were dichotomized: ≤13 taken as no or minimal depression,
and $\geq 14$ as presence of depression—be it mild, moderate, or severe [29].

Treating physicians, as part of their routine monitoring of adverse events, recorded their subjective estimation of depression occurrence at each office visit and provided an opinion as to whether there was a relationship between treatment given and depression in patients thought to be depressed.

**Antidepressant usage**

Information on antidepressant use by study participants was collected at each office visit. The co-medication database was searched using the following search terms: “antidepressants,” “selective serotonin reuptake inhibitors,” “nonselective monoamine reuptake inhibitors,” “nonselective monoamine oxidase inhibitors,” “monoamine oxidase A inhibitors,” “other antidepressants,” “antidepressants in combination with psycholeptics,” and “lithium.”

**Statistics**

Descriptive statistics and Fisher’s exact test at the 0.05 level of significance (post hoc) were used for data analyses.

**Results**

**Study population**

Altogether, 2244 patients were randomized in the multinational BEYOND study. The majority were female (1562/2244; 69.6 %) and Caucasian (2045/2242; 91.2 %). Most patients (1786/2244; 79.6 %) had an EDSS score at screening of 1.0–3.5. The mean age at disease onset was $31.0 \pm 9.1$ years and mean disease duration was $5.3 \pm 5.8$ years (Table 1). A total of 24 patients did not receive treatment with study medication and accordingly were omitted from the per-protocol analysis. Baseline demographics and disease characteristics were similar across the treatment groups, as described in more detail elsewhere [25].

**Depression assessed by BDI-II**

The BDI-II enabled assessment of patients from Australia, Canada, the USA, France, Italy, and Spain. Validated language versions were not available for 60.0 % (1347/2244) of randomized patients. A total of 39.7 % of randomized patients (891/2244) had BDI-II scores recorded at screening (proportion in each treatment arm: IFNB-1b 500 $\mu$g, 40.2 % [361/899]; IFNB-1b 250 $\mu$g, 39.8 % [357/897]; GA, 38.6 % [173/448]). Only six patients eligible for BDI-II testing did not perform a screening assessment. Of patients with screening BDI-II scores, 74.0 % overall (659/891) had BDI-II scores $\leq 13$, indicating no or minimal depression, while 26.0 % (232/891) had scores $\geq 14$, suggesting mild to severe depression (proportion in each treatment arm: IFNB-1b 500 $\mu$g, 24.7 % [89/361]; IFNB-1b 250 $\mu$g, 24.4 % [87/357]; GA, 32.4 % [56/173]). No significant differences in depression severity were found between treatment arms at screening (IFNB-1b 500 $\mu$g vs. GA, $p = 0.062$; IFNB-1b 250 $\mu$g vs. GA, $p = 0.060$).

Patients with BDI-II scores $\geq 14$ had higher baseline EDSS scores ($p < 0.0001$) and more relapses in the 2 years prior to enrollment ($p = 0.0017$) than patients with scores $\leq 13$ (Table 2). However, patients with higher baseline depression scores had fewer gadolinium-enhancing lesions and lower gadolinium-enhancing lesion volume at baseline.

| Table 1 Baseline characteristics of participants randomized in the BEYOND study |
|-----------------|-----------------|-----------------|-----------------|-----------------|
|                 | IFNB-1b 500 $\mu$g | IFNB-1b 250 $\mu$g | GA              | Total           |
|                 | $n = 899$        | $n = 897$        | $n = 448$       | $N = 2244$      |
| Duration of disease |                 |                 |                 |                 |
| $N$             | 899             | 896             | 448             | 2243            |
| Mean (range, SD), years | 5.4 (0–33, 5.8) | 5.3 (0–42, 5.8) | 5.1 (0–29, 5.6) | 5.3 (0–42, 5.8) |
| Age at onset |                 |                 |                 |                 |
| $N$             | 899             | 896             | 448             | 2243            |
| Mean (range, SD), y | 31.1 (9–55, 9.2)| 31.1 (10–53, 9.2)| 30.6 (8–55, 9.0)| 31.0 (8–55, 9.1) |
| Number of relapses during the previous year |                 |                 |                 |                 |
| $N$             | 899             | 896             | 448             | 2243            |
| Mean (range, SD), |                 |                 |                 |                 |
| $N$             | 894             | 888             | 448             | 2230            |
| Mean (range, SD), |                 |                 |                 |                 |
| BEYOND Betaseron Efficacy Yielding Outcomes of a New Dose [trial], GA glatiramer acetate, IFNB-1b interferon beta-1b |
## Table 2 Baseline characteristics of patients by BDI-II scores at screening

| Characteristic                                                                 | Screening BDI-II score ≤ 13 | Screening BDI-II score ≥ 14 |
|--------------------------------------------------------------------------------|------------------------------|-----------------------------|
|                                                                                  | \( n = 659 \)                | \( n = 232 \)               |
| Female                                                                          |                              |                             |
| \( n/N \)                                                                       | 479/659 (72.7 %)             | 181/232 (78.0 %)            |
| \( p \) value                                                                  | 0.1175                       |                             |
| Caucasian                                                                       |                              |                             |
| \( n/N \)                                                                       | 577/658 (87.7 %)             | 195/231 (84.4 %)            |
| \( p \) value                                                                  | 0.2141                       |                             |
| Age                                                                             |                              |                             |
| \( N \)                                                                        | 659                          | 232                         |
| Mean (range, SD), years                                                        | 38.0 (18–57, 9.1)            | 38.0 (18–55, 9.0)           |
| \( p \) value                                                                  | 0.8577                       |                             |
| Duration of disease                                                            |                              |                             |
| \( N \)                                                                        | 659                          | 232                         |
| Mean (range, SD), years                                                        | 4.7 (0–42, 5.8)              | 4.9 (0–32, 5.7)             |
| \( p \) value                                                                  | 0.4159                       |                             |
| Relapse rate in the previous 2 years                                            |                              |                             |
| \( N \)                                                                        | 657                          | 232                         |
| Mean (range, SD)                                                               | 1.9 (1.0–10.0, 1.0)          | 2.2 (1.0–15.0, 1.3)         |
| \( p \) value                                                                  | 0.0017                       |                             |
| Two or more relapses in the previous 2 years                                    |                              |                             |
| \( n/N \)                                                                       | 433/657 (65.9 %)             | 173/232 (74.6 %)            |
| \( p \) value                                                                  | 0.0173                       |                             |
| EDSS                                                                            |                              |                             |
| \( N \)                                                                        | 651                          | 227                         |
| Mean (range, SD)                                                               | 2.0 (0–5.5, 1.1)             | 2.7 (0–6.0, 1.2)            |
| \( p \) value                                                                  | <0.0001                      |                             |
| T2 lesion volume (cm\(^3\))                                                   |                              |                             |
| \( N \)                                                                        | 657                          | 230                         |
| Mean (range, SD)                                                               | 7.0 (0.1–72.7, 8.4)          | 6.6 (0.1–102.0, 9.6)        |
| \( p \) value                                                                  | 0.2312                       |                             |
| T1-hypointense lesion volume (cm\(^3\))                                        |                              |                             |
| \( N \)                                                                        | 648                          | 227                         |
| Mean (range, SD)                                                               | 1.2 (0–26.1, 2.5)            | 1.1 (0–39.1, 2.9)           |
| \( p \) value                                                                  | 0.3305                       |                             |
| One or more Gd-enhancing lesions                                               |                              |                             |
| \( n/N \)                                                                       | 295/659 (44.8 %)             | 82/232 (35.3 %)             |
| \( p \) value                                                                  | 0.0134                       |                             |
| Gd-enhancing lesion volume (cm\(^3\))                                          |                              |                             |
| \( N \)                                                                        | 651                          | 229                         |
| Mean (range, SD)                                                               | 0.22 (0–6.7, 0.6)            | 0.16 (0–5.8, 0.5)           |
| \( p \) value                                                                  | 0.0163                       |                             |
| Normalized brain volume (cm\(^3\))                                             |                              |                             |
| \( N \)                                                                        | 648                          | 228                         |
| Mean (range, SD)                                                               | 1502.9 (1171–1804, 106.7)    | 1494.7 (1142–1764, 103.2)   |
| \( p \) value                                                                  | 0.3121                       |                             |

*BDI-II* Beck Depression Inventory Second Edition, *EDSS* Expanded Disability Status Scale, *Gd* gadolinium
The frequency with which depression was reported as an adverse event by non-blinded treating physicians was similar for IFNB-1b 500 μg (299/887; IFNB-1b 250 μg, 31.8 % (282/888); GA, 28.8 % (128/445) (IFNB-1b 500 μg vs. GA, p = 0.07; IFNB-1b 250 μg vs. GA, p = 0.28).

**Antidepressant usage**

The proportions of patients treated with antidepressant medication at some point during the BEYOND study were similar across the treatment arms: IFNB-1b 500 μg, 33.7 % (299/887); IFNB-1b 250 μg, 31.8 % (282/888); GA, 28.8 % (128/445) (IFNB-1b 500 μg vs. GA, p = 0.40; IFNB-1b 250 μg vs. GA, p = 0.24) (Fig. 3).

**Discussion**

The incidence and severity of depression in RRMS patients treated with either of two doses of IFNB-1b or with GA in the multinational BEYOND clinical trial were evaluated prospectively using a validated instrument for assessing depression. The exclusion of patients with a clinical history of severe depression, attempted suicide or suicidal ideation reduced the potential confounders for this analysis. Twenty-six percent of entrants had a BDI-II score ≥14 at screening, indicative of depression of at least mild severity. Patients with BDI-II scores ≥14 at screening had higher relapse rates in the 2 years preceding entry and higher EDSS scores at baseline than patients with BDI-II scores <13. Intriguingly, they also had fewer gadolinium-enhancing lesions, suggesting that clinically apparent relapses might be a more reliable indicator of depression than gadolinium positivity.

At trial entry, numerically fewer patients randomly assigned to IFNB-1b (either dose) had BDI-II total scores indicative of clinical depression than patients assigned to GA. These differences, while minor, persisted over the...
Fig. 1  Number of patients with BDI-II scores at selected time points stratified by BDI-II score at screening and treatment assignment. Fisher’s exact test was used for comparison.

A

**IFNB-1b 500 µg**

| Screening | Week 13 | Week 26 | Week 52 | End of Study |
|-----------|---------|---------|---------|--------------|
| ≤13 | 272 | 264 | 257 | 250 | 248 |
| ≥14 | 89 | 67 | 85 | 81 | 73 |

Proportion with BDI-II score ≥14:
- ≤13: 24.7%
- ≥14: 24.2%
- ≤13: 26.9%
- ≥14: 27.2%
- ≤13: 27.4%
- ≥14: 27.4%

p value versus glatiramer acetate:
- 0.062
- 0.663
- 0.748
- 0.830
- 0.515

B

**IFNB-1b 250 µg**

| Screening | Week 13 | Week 26 | Week 52 | End of Study |
|-----------|---------|---------|---------|--------------|
| ≤13 | 270 | 258 | 261 | 255 | 244 |
| ≥14 | 87 | 79 | 81 | 74 | 75 |

Proportion with BDI-II score ≥14:
- ≤13: 24.4%
- ≥14: 25.8%
- ≤13: 26.3%
- ≥14: 24.9%
- ≤13: 28.8%
- ≥14: 28.8%

p value versus glatiramer acetate:
- 0.060
- 1.000
- 0.592
- 0.444
- 0.747

C

**Glatiramer acetate**

| Screening | Week 13 | Week 26 | Week 52 | End of Study |
|-----------|---------|---------|---------|--------------|
| ≤13 | 117 | 112 | 110 | 110 | 106 |
| ≥14 | 56 | 53 | 51 | 50 | 48 |

Proportion with BDI-II score ≥14:
- ≤13: 32.4%
- ≥14: 26.1%
- ≤13: 28.6%
- ≥14: 28.1%
- ≤13: 30.5%
course of the trial, although they never reached significance at any time point. More importantly, similar proportions of patients in all three arms without depression at study entry progressed to BDI-II scores indicative of depression during the trial, while comparative numbers of patients in all three arms with BDI-II score suggestive of depression at study entry reverted to non-depressed status during the trial. These two trends largely offset one another, such that the incidence of depression remained relatively constant among all three arms throughout the course of the trial.

Antidepressant usage was likewise comparable across all three treatment arms.

Despite the above, treating physicians were far more likely to cite depression as a complication of IFNB-1b treatment than as a complication of GA treatment. Labels for IFNB warn of depression and suicide, whereas labels for GA carry no such warning; this difference may have accounted for an attribution bias. Although the non-blinding of physicians could be considered a limitation of the study, the frequency with which non-blinded treating physicians clinically stated depression as an adverse event was substantially lower than the frequency with which depression was suggested by the BDI-II across all three treatment groups. Thus, the data presented here suggest that awareness of the patient’s treatment did not substantially influence reporting of clinical depression and underscore the value of screening with a validated instrument to get a full sense of depression frequency in MS.

Another possible limitation of the present study is the absence of a placebo-treated control group. Consequently, the issue of whether IFNB-1b and GA therapies are both associated with depression, or neither therapy is so associated, cannot be resolved definitively by the available data presented here. In addition, only a relatively small percentage of patients (approximately, 40 %) completed the BDI. However, it is important to note that the percentage of patients with BDI data in each treatment group was similar. Nonetheless, the present study provides strong support to a considerable body of literature favoring the view that neither agent is linked to aggravating or inducing clinical depression. First, GA has not been perceived to be associated with depression in placebo-controlled or open-label studies nor as a spontaneously reported adverse event. Second, outcomes from the BEYOND study match data generated in other randomized, placebo-controlled trials of IFNB: no significant difference in the occurrence of patient-reported depression was found between IFNB-1b and placebo in the original IFNB-1b trial [30]. Similarly, in the 2-year study comparing intramuscular IFNB-1a with

---

**Fig. 2** Proportion of patients with a BDI scores ≤13 at screening who had BDI-II scores of ≥14 at the end of the study (n = 794); b BDI-II scores ≥14 at screening who had BDI-II scores ≤13 at the end of the study (n = 794). Fisher’s exact test was used for comparison.
placebo, BDI-II scores did not differ at any time point between treatment groups [6]. In the “Prevention of Relapses and Disability by IFNB-1a Subcutaneously in Multiple Sclerosis” (PRISMS) study, no relationship between IFNB-1a treatment and clinically significant depression was found over 24 months (relative risk, 0.3–1.8) compared with placebo [31]. Furthermore, in a pooled analysis of 6 controlled studies and 17 non-controlled trials, subcutaneous IFNB-1a therapy was not linked to an increase in depression severity or suicide risk [22] and a controlled, epidemiologic study that assessed depression in 50 Italian RRMS patients and 50 healthy controls using a variety of methods (Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders (DSM-IV), BDI, and State Trait Anxiety Inventory) concluded that IFNB therapy was not a risk factor for depression [32]. A sizable head-to-head (n = 764) clinical trial comparing subcutaneous IFNB-1a versus GA found no significant differences in the proportions of patients reporting depression as an adverse event [33]. Last, IFNB-1b- and GA-treated patients identified in a health-care database exhibited no differences in antidepressant usage, a useful proxy for depression incidence [34]. Collectively, these data—reinforced by the results presented here—provide compelling evidence to support the hypothesis that IFNB neither causes nor exacerbates depression in patients with MS.

We recognize that MS patients with a history of depression may be more vulnerable to subsequent depression than those without such a history, and that disease activity may herald future depression. In the BEYOND study, patients with active depression or a clinical history of severe depression were excluded, and the majority of participants exhibited low disease activity over the 3-year study duration. While the absence of patients with a previous history of depression in the BEYOND study population may limit the generalizability of our findings, no biological signal was detected in this patient cohort and IFNB-1b was not found to induce or exacerbate depressive symptoms.

Acknowledgments The authors thank the members of the independent data safety monitoring board for the BEYOND study (Stephen Reingold, Jerry S Wolinsky, Chris H Polman, Per Soelberg Sorensen, and Thomas Fleming). Dr Reingold also provided input on an early version of the manuscript. This paper was drafted by Sven Schippling, Barry Arnason, and Volker Knappertz, with medical writing support (assistance with drafting the manuscript under the direction of the authors) from Tiffany DeSimone and Ray Ashton of PAREXEL. Maria Bell and Caroline Neville of PAREXEL copypedited (reviewed grammar, consistency and spelling) and styled the manuscript. PAREXEL’s support was funded by Bayer HealthCare Pharmaceuticals. Sven Schippling is supported by the Clinical Research Priority Program of the University of Zurich, the Betty and David Koetsier Foundation for Brain Research, and the Swiss MS Society.

Funding The BEYOND study was funded by Bayer HealthCare Pharmaceuticals.

Compliance with ethical standards

Conflicts of interest SS has received research grants from Biogen Idec and Bayer Schering Pharma and consulting/speaker fees from Bayer Schering Pharma, Biogen Idec, Merck Serono, Novartis, and Sanofi-Aventis. POC has received either personal compensation (for consulting, serving on a scientific advisory board, or speaking) or financial support for scholarly activities from pharmaceutical companies that develop products for multiple sclerosis, including Biogen Idec, Sanofi-Aventis, EMD Serono, Abbott, Teva, Bayer, Bio-MS, Genentech, Genzyme, Roche, and Novartis. VK is a salaried employee of Teva Pharmaceuticals. He was a salaried employee of Bayer HealthCare Pharmaceuticals when the manuscript was developed and is currently a salaried employee of Teva Pharmaceuticals. CP was a salaried employee of Bayer HealthCare AG/Bayer Pharma AG, Berlin, Germany. TB is a salaried employee of Bayer HealthCare AG/Bayer Pharma AG, Berlin, Germany. GS is a salaried employee of Bayer HealthCare Pharmaceuticals, Whippany, New Jersey. SC’s institution has received grant support for his involvement in clinical trials. He has received personal compensation from Bayer HealthCare Pharmaceuticals, Biogen Idec, Sanofi-Aventis, Teva, and Merck Serono for consulting services, board membership, and/or lectures. MF serves on scientific advisory boards for Teva and Genmab; has received funding for travel from Bayer Schering Pharma, Biogen-Dompé, Genmab, Merck Serono, and Teva; serves on editorial boards of the American Journal of Neuroradiology, BMC Musculoskeletal Disorders, Clinical Neurology and Neurosurgery, Ervera Medical Journal, Journal of Alzheimer’s Disease, Journal of Neuroimaging, Journal of Neurovirology, Magnetic Resonance Imaging, Multiple Sclerosis, and Neurological Sciences; serves as a consultant to Bayer Schering Pharma, Biogen-Dompé, Genmab, Merck Serono, and Teva; serves on speakers’ bureaus for Bayer Schering Pharma, Biogen-Dompé, Genmab, Merck Serono, and Teva; and receives research support from Bayer Schering Pharma, Biogen-Dompé, Genmab, Merck Serono, Teva, and Fondazione Italiana Sclerosi Multipla. HPH has received honoraria for consulting and speaking at symposia from Bayer Pharma AG, Biogen Idec, Genzyme, GeNeuro, Octapharma, Merck Serono, Novartis, Roche, Teva, and Sanofi-Aventis, with approval by the rector of Heinrich-Heine University. GC has received personal compensation for speaking and consultancy activities from Bayer Schering, Serono Symposia International Foundation, Merck Serono, Sanofi-Aventis, Novartis, Biogen Dompé, and Teva in the past 2 years. DRJ has received honoraria and consulting fees from Berlex, Serono, Teva, Glaxo, and Pfizer. LK’s institution, (University Hospital Basel) received in the last 3 years and used exclusively for research support: steering committee/consulting fees from Actelion, Addex, Bayer HealthCare, Biogen, Biotica, Genzyme, Lilly, Merck, Mitsubishi, Novartis, Ono, Pfizer, Receptos, Sanofi-Aventis, Santthera, Siemens, Teva, UCB, and Xenoprot; speaker fees from Bayer HealthCare, Biogen, Merck, Novartis, Sanofi-Aventis, and Teva; support of educational activities from Bayer HealthCare, Biogen, CSL Behring, Genzyme, Merck, Novartis, Sanofi-Aventis, and Teva; support of educational activities from Bayer HealthCare, Biogen, the European Union, Merck, Novartis, Roche, Roche Research Foundations, the Swiss Multiple Sclerosis Society, and the Swiss National Research Foundation. DSG has participated (or is currently participating) in several industry-sponsored clinical trials in MS. The sponsoring pharmaceutical companies for these trials have included (or do include) Ares-Serono, Merck Serono, Novartis, Berlex, Bayer Schering Pharma, Biogen Idec, Schering, and Teva Neuroscience. He has also lectured at both medical conferences and in public on various aspects of the epidemiology, diagnosis, and management of MS. In many cases, these talks have been sponsored
directly or indirectly by one or the other of the above-listed companies. He has also served as a temporary ad hoc consultant to several of these organizations on several occasions. BA has served as a consultant within the past year to Bayer Schering, Sanofi-Aventis, Questcor, and Acorda. He has participated in a clinical trial sponsored by Acorda and has received research grant support from Questcor.

**Ethical standards** The institutional review boards of all participating centers approved the protocol for this study and all procedures were in accordance with the ethical standards laid down in the Declaration of Helsinki. All patients provided written informed consent before starting the study.

**Open Access** This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

**References**

1. Compton A, Coles A (2008) Multiple sclerosis. Lancet 372(9648):1502–1517
2. Chwastiak LA, Ehde DM (2007) Psychiatric issues in multiple sclerosis. Psychiatry Clin North Am 30(4):803–817
3. Paparrigopoulos T, Ferentinos P, Kouzoupis A, Koutsis G, Papadimitriou GN (2010) The neuropsychiatry of multiple sclerosis: focus on disorders of mood, affect and behaviour. Int Rev Psychiatry 22(1):14–21
4. Beal CC, Stuifbergen AK, Brown A (2007) Depression in multiple sclerosis: a longitudinal analysis. Arch Psychiatry Nurs 21(4):181–191
5. Dahl OP, Stordal E, Lydersen S, Midgard R (2009) Anxiety and depression in multiple sclerosis. A comparative population-based study in Nord-Trondelag County, Norway. Muli Scler 15(12):1495–1501
6. Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM et al (1996) Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 39(3):285–294
7. Kessler RC, Berglund P, Demler O, Jin R, Koretz D, Merikangas KR et al (2003) The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 289(23):3095–3105
8. Minden SL, Orav J, Reich P (1987) Depression in multiple sclerosis. Gen Hosp Psychiatry 9(6):426–434
9. Patten SB, Metz LM, Reimer MA (2000) Biopsychosocial correlates of lifetime major depression in a multiple sclerosis population. Muli Scler 6(2):115–120
10. Patten SB, Beck CA, Williams JV, Barbui C, Metz LM (2003) Major depression in multiple sclerosis: a population-based perspective. Neurology 61(1):1524–1527
11. Sadovnick AD, Remick RA, Allen J, Swartz E, Yee IM, Eisen K et al (1996) Depression and multiple sclerosis. Neurology 46(3):628–632
12. Schubert DS, Foliart RH (1993) Increased depression in multiple sclerosis patients, a meta-analysis. Psychosomatics 34(2):124–130
13. Williams RM, Turner AP, Hatzakis M Jr, Bowen JD, Rodriguez AA, Haselkorn JK (2005) Prevalence and correlates of depression among veterans with multiple sclerosis. Neurology 64(1):75–80
14. Scalfari A, Knappertz V, Cutter G, Goodin DS, Ashton R, Ebers GC (2013) Mortality in patients with multiple sclerosis. Neurology 81(2):184–192
15. Ebers GC (1998) Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing-remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet 352(9139):1498–1504
16. Betaseron [package insert]. Montville, NJ: Bayer HealthCare Pharmaceuticals; 2010
17. Avonex [package insert]. Cambridge, MA: Biogen Idec Inc; 2012
18. Rebif [package insert]. Rockland, MA: EMD Serono; 2012
19. Extavia [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2012
20. Lana-Peixoto MA, Teixeira AL, Jr, Haase VG (2002) Interferon beta-1a-induced depression and suicidal ideation in multiple sclerosis. Arq Neuropsiquiatr 60(3-B):721–724
21. Mohr DC, Hart SL, Fonareva I, Tasch ES (2006) Treatment of depression for patients with multiple sclerosis in neurology clinics. Muli Scler 12(2):204–208
22. Patten SB, Francis G, Metz LM, Lopez-Bresnahan M, Chang P, Curtin F (2005) The relationship between depression and interferon beta-1a therapy in patients with multiple sclerosis. Muli Scler 11(2):175–181
23. Mohr DC, Likosky W, Boudewyn AC, Marietta P, Dwyer P, Van der WJ et al (1998) Side effect profile and adherence to in the treatment of multiple sclerosis with interferon beta-1a. Muli Scler 4(6):487–489
24. Feinstein A (2007) Neuropsychiatric syndromes associated with multiple sclerosis. J Neurol 254(Suppl 2):H73–H76
25. O’Connor P, Filipp M, Amason B, Comi G, Cook S, Goodin D et al (2009) 250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurol 8(10):889–897
26. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD et al (2001) Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 50(1):121–127
27. Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33(11):1444–1452
28. Beck A, Brown G, Steer R (1996) Beck depression inventory-II manual. The Psychological Corporation
29. Goldberg Consensus Group (2005) The Goldman Consensus statement on depression in multiple sclerosis. Muli Scler 11(3):328–337
30. The IFNB Multiple Sclerosis Study Group (1993) Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43(4):655–661
31. Patten SB, Metz LM (2001) Interferon beta-1a and depression in relapsing-remitting multiple sclerosis: an analysis of depression data from the PRISMS clinical trial. Muli Scler 7(4):243–248
32. Galeazzi GM, Ferrari S, Girolini R, Mackinnon A, Merelli E, Motti L et al (2005) Psychiatric disorders and depression in multiple sclerosis outpatients: impact of disability and interferon beta-1a therapy. Neurol Sci 26(4):255–262
33. Mikol DD, Burkhof F, Chang P, Coyle PK, Jeffery DR, Schwid SR et al (2008) Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the Rebif vs Glatiramer Acetate in Relapsing MS Disease [ REGARD] study): a multicentre, randomised, parallel, open-label trial. Lancet Neurol 7(10):903–914
34. Patten SB, Williams JV, Metz LM (2008) Anti-depressant use in association with interferon and glatiramer acetate treatment in multiple sclerosis. Muli Scler 14(3):406–411